The following drugs have been approved since the year 2000 for the treatment of non-Hodgkin's lymphoma:
FDA approved October 2008
Bendamustine is a chemotherapy drug approved for the treatment of B-cell non-Hodgkin lymphomas.
FDA approved October 2005
This chemotherapy drug is approved for the treatment of T-cell lymphoblastic lymphoma.
FDA approved June 2003
This drug is a monoclonal antibody that targets specific lymphoma cells. Tositumomab is linked to a radioactive agent called iodine-131 (I-131). The medicine allows radiation to be delivered directly to the sites of the lymphoma.
Zevalin (ibritumomab tiuxetan)
FDA approved February 2002
This drug is a protein that targets specific lymphoma cells. To be effective ibritumomab tiuxetan is linked to a radioactive agent called yttrium chloride (Y-90). The medicine allows radiation to be delivered directly to the sites of the lymphoma.
Planning a visit to Sentara RMH? Take a tour of our campus before you come.
Talk to Us
Sentara RMH appreciates your feedback.
Sign up for updates and news from Sentara RMH!
Enter your email address below to receive health and news updates from RMHOnline.com!